J. Parnell

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy

R. Sheth, B. Gidal, M. Sale, 2003, Epilepsy Research.

Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists

M. Sanjak, B. Brooks, D. Belden, 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

C. Bever, L. Weiner, J. Wolinsky, 2000, Multiple Sclerosis.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

J S Wolinsky, J. Wolinsky, P. Narayana, 2001, Multiple sclerosis.